NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

NeuroOne Medical Technologies Corporation (NMTC) Stock Analysis

NeuroOne Medical Technologies Corporation (NMTC) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

NMTC

$1.62

−$0.04 (−2.41%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NMTC with… →

NMTC Key Statistics

As of Sep 4, 2026
Trading
Open
$1.65
Previous Close
$1.66
Day's Range
1.57–1.66
52-Week Range
1.42–6.96
Volume
81.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.64
Valuation
Market Cap
$14.75M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.18
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.97
Financials (FY)
Revenue (FY)
$9.10M+163.47%
Net Income (FY)
−$3.61M
Profit marginThe share of revenue left as profit after all costs and taxes.
−59.71%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.11M
1-Year Return
−63.06%
Dividend and dates
Avg Volume
290.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NMTC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−64.38%
2025−8.23%
2024−47.72%
2023+31.67%
2022−38.14%
2021−58.81%
2020−34.03%
2019−57.19%
2018 (partial year)+38.31%

As of September 4, 2026.

NMTC Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$9.10M−$3.61M−39.6%
2024$3.45M−$12.32M−356.7%
2023$1.95M−$11.86M−607.4%
2022$171.17K−$10.00M−5842.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$9.10M$5.14M−$4.23M−$3.61M−39.6%
2024$3.45M$1.08M−$11.89M−$12.32M−356.7%
2023$1.95M$456.52K−$11.96M−$11.86M−607.4%
2022$171.17K−$70.79K−$10.03M−$10.00M−5842.0%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

NMTC Valuation vs Medical Devices Median

Median of 151 stocks
MetricNMTCMedical Devices medianvs median
P/S ratio1.182.9860% below
Profit margin−59.71%−1.69%58.0 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values NeuroOne Medical Technologies Corporation (NMTC) at $14.75M. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 18 employees.

The 52-week range on file runs from $1.42 to $6.96. The most recent close on file for NMTC is $1.62, dated September 4, 2026. That is −$0.04 (−2.41%) against the previous close. The latest close sits 13.84% above that 52-week low.

Financial Health

In fiscal 2025, NeuroOne Medical Technologies Corporation reported revenue of $9.10M. Against the prior fiscal year total of $3.45M, that is a change of +163.47%. The same year closed with a net loss of $3.61M. Profit margin runs at −59.71%. That is 58 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −0.97.

Across the 4 fiscal years on file, revenue moves from $171.17K in 2022 to $9.10M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 1.18. On price-to-sales that is 60.25% below the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.64. Annualized volatility over the trailing 8 years is 106.6%. The trailing one-year price return is −63.06%. Measured over 5 years, that is −43.57% a year compounded.

Growth & Income

No dividend is on file for NMTC.

The strongest complete calendar year on file is 2023 at +31.67%; the weakest is 2021 at −58.81%. Of the 7 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −64.38% year to date.

Peer Comparison

NeuroOne Medical Technologies Corporation (NMTC) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NeuroOne Medical Technologies Corporation NMTC $14.75M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. NeuroOne Medical Technologies Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.

Visit website →